Robert Millham brings to CATO SMS more than 20 years of leadership experience across global pharmaceutical, biotech and contract research organizations (CROs). He has spearheaded scientific teams, clinical development programs and operations worldwide to drive the success of cancer therapeutics throughout his career. Highlights of Mr. Millham’s accomplishments include: leading and contributing to the development of compounds against multiple indications of cancer including lung, breast, colorectal and ovarian over a 17-year career at Pfizer; overseeing drug development activities and opening a pivotal phase 3 clinical trial in metastatic breast cancer while advancing the company’s growth as COO of Odonate Therapeutics; and leading the Oncology Center of Excellence, as well as clinical trial management initiatives, for a variety of biotech and pharmaceutical clients as Senior Vice President at Syneos Health. In his most recent position as Vice President of Strategic Alliances for Caris Life Sciences, he grew and developed the organization’s Precision Oncology Alliance network.
Mr. Millham has authored and co-authored multiple peer-reviewed articles, abstracts and presentations over the past 20 years. He earned a master’s degree in pharmaceutical medicine from Hibernia College in Dublin, Ireland, as well as a master’s degree in microbiology from the University of New Hampshire. He holds a bachelor’s degree in biology from Middlebury College.